Novartis receives positive CHMP opinion for Jakavi® to
CHMP opinion based on Phase III REACH2 and REACH3 trials that showed Jakavi improved response rates and failure-free survival compared to best available therapy1,2 Graft-versus-host disease (GvHD) is a serious ...
